APA (7th ed.) Citation

Cortesi, P. A., Antonazzo, I. C., Palladino, P., Gnesi, M., Mele, S., D’Amelio, M., . . . Mantovani, L. G. (2024). Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting. Acta Diabetologica, 61(8), 1017-1028. https://doi.org/10.1007/s00592-024-02276-3

Chicago Style (17th ed.) Citation

Cortesi, Paolo Angelo, Ippazio Cosimo Antonazzo, Pasquale Palladino, Marco Gnesi, Silvia Mele, Marco D’Amelio, Elena Zanzottera Ferrari, Giampiero Mazzaglia, and Lorenzo Giovanni Mantovani. "Health and Economic Impact of Dapagliflozin for Type 2 Diabetes Patients Who Had or Were at Risk for Atherosclerotic Cardiovascular Disease in the Italian General Practitioners Setting." Acta Diabetologica 61, no. 8 (2024): 1017-1028. https://doi.org/10.1007/s00592-024-02276-3.

MLA (9th ed.) Citation

Cortesi, Paolo Angelo, et al. "Health and Economic Impact of Dapagliflozin for Type 2 Diabetes Patients Who Had or Were at Risk for Atherosclerotic Cardiovascular Disease in the Italian General Practitioners Setting." Acta Diabetologica, vol. 61, no. 8, 2024, pp. 1017-1028, https://doi.org/10.1007/s00592-024-02276-3.